Inclusion-body myositis

Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and there is no successful treatment. We summarize our most recent findings, which provide a better understanding of the steps in the pathogenetic cascade. We suggest that s-IBM is primarily a myodegenerative disease. Intriguing are the phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer disease, the most common neurodegenerative disease of older persons. In s-IBM, abnormal accumulation of the amyloid-β (Aβ) precursor protein and its proteolytic fragment, Aβ, associated with the aging intracellular milieu of the muscle fiber, appear to be key upstream pathogenic events. We propose that the identified abnormal accumulation, misfolding, and aggregation of proteins, perhaps provoked by the aging milieu and aggravated by the oxidative stress, lead to the s-IBM-specific vacuolar degeneration and atrophy of muscle fibers.

[1]  Dominic M. Walsh,et al.  Certain Inhibitors of Synthetic Amyloid β-Peptide (Aβ) Fibrillogenesis Block Oligomerization of Natural Aβ and Thereby Rescue Long-Term Potentiation , 2005, The Journal of Neuroscience.

[2]  Z. Simmons,et al.  Sporadic inclusion body myositis and hereditary inclusion body myopathy. , 2002, Journal of clinical neuromuscular disease.

[3]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[4]  Richard J. Barohn,et al.  Inclusion body myositis , 2000, Current treatment options in neurology.

[5]  J. Growdon,et al.  Elevation of cystatin C in susceptible neurons in Alzheimer's disease. , 2001, The American journal of pathology.

[6]  C. Link,et al.  Interaction of intracellular β amyloid peptide with chaperone proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[8]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[9]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[10]  Andrew G. Engel,et al.  αB-Crystallin immunolocalization yields new insights into inclusion body myositis , 2000, Neurology.

[11]  C. Glabe Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. , 2005, Sub-cellular biochemistry.

[12]  R. Griggs The current status of treatment for inclusion-body myositis , 2006, Neurology.

[13]  R. Kaufman,et al.  ER stress and the unfolded protein response. , 2005, Mutation research.

[14]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[15]  B. Ghetti,et al.  Codeposition of Cystatin C with Amyloid‐β Protein in the Brain of Alzheimer Disease Patients , 2001, Journal of neuropathology and experimental neurology.

[16]  Changcheng Song,et al.  Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. , 2004, Journal of structural biology.

[17]  K. Hall,et al.  Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans , 2000, Neurology.

[18]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[19]  W. Engel,et al.  Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-&bgr;, misfolded proteins, predisposing genes, and aging , 2003, Current opinion in rheumatology.

[20]  W. Klein ADDLs & protofibrils—the missing links? , 2002, Neurobiology of Aging.

[21]  L. Pasquini,et al.  Relationship between β-amyloid degradation and the 26S proteasome in neural cells , 2003, Experimental Neurology.

[22]  W. Engel,et al.  βAPP gene transfer into cultured human muscle induces inclusion‐body myositis aspects , 1997 .

[23]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[24]  Jason E Gestwicki,et al.  Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation , 2004, Science.

[25]  A. Goldberg,et al.  Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.

[26]  Julio C. Echegoyen,et al.  Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Cuello,et al.  Intracellular A-beta amyloid, A sign for worse things to come? , 2002, Molecular Neurobiology.

[28]  C. Pickart,et al.  Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Engel,et al.  Inclusion‐Body Myositis: Newest Concepts of Pathogenesis and Relation to Aging and Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[30]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[31]  P. Højrup,et al.  Proteasomal inhibition by alpha-synuclein filaments and oligomers. , 2004, The Journal of biological chemistry.

[32]  D. Ron,et al.  Conformational disease , 2000, Nature Cell Biology.

[33]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[34]  J R Lindsey,et al.  Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. , 1998, The American journal of pathology.

[35]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[36]  E. Hol,et al.  Disease‐specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Rahul S. Rajan,et al.  Specificity in intracellular protein aggregation and inclusion body formation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Kucharz Ej [Inclusion body myositis]. , 1998, Polskie Archiwum Medycyny Wewnetrznej.

[39]  E. Hol,et al.  Molecular misreading: a new type of transcript mutation expressed during aging , 2000, Neurobiology of Aging.

[40]  R. Nitsch,et al.  Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease , 2003, Journal of neurochemistry.

[41]  M. Dalakas The molecular and cellular pathology of inflammatory muscle diseases. , 2001, Current opinion in pharmacology.

[42]  P M Steinert,et al.  Sporadic Inclusion Body Myositis Correlates with Increased Expression and Cross-linking by Transglutaminases 1 and 2* , 2000, The Journal of Biological Chemistry.

[43]  W. Engel,et al.  Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle , 2002, Neurology.

[44]  S. Silberstein,et al.  Acute migraine treatment with droperidol , 2003, Neurology.

[45]  J. Buxbaum,et al.  BACE1 and BACE2 in pathologic and normal human muscle , 2003, Experimental Neurology.

[46]  A. Fink Chaperone-mediated protein folding. , 1999, Physiological reviews.

[47]  C. Fielding,et al.  Cholesterol and caveolae: structural and functional relationships. , 2000, Biochimica et biophysica acta.

[48]  W. Engel,et al.  Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. , 1998, The American journal of pathology.

[49]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[50]  V. Askanas,et al.  Cystatin C colocalizes with amyloid‐β and coimmunoprecipitates with amyloid‐β precursor protein in sporadic inclusion‐body myositis muscles , 2003 .

[51]  W. Engel,et al.  Does Overexpression of βAPP in Aging Muscle Have a Pathogenic Role and a Relevance to Alzheimer’s Disease? : Clues from Inclusion Body Myositis, Cultured Human Muscle, and Transgenic Mice , 1998 .

[52]  E. Sztul,et al.  Hassles with Taking Out the Garbage: Aggravating Aggresomes , 2002, Traffic.

[53]  W. Engel,et al.  Myostatin is increased and complexes with amyloid-β within sporadic inclusion-body myositis muscle fibers , 2005, Acta Neuropathologica.

[54]  W. Engel,et al.  Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion‐body myopathies , 1998, Neuroreport.

[55]  W. Engel,et al.  Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. , 2004, The American journal of pathology.

[56]  J. Buxbaum,et al.  Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis , 2001, The Lancet.

[57]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[58]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[59]  George M. Martin,et al.  Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis , 1998 .

[60]  A. Pockley,et al.  Heat shock proteins in health and disease: therapeutic targets or therapeutic agents? , 2001, Expert Reviews in Molecular Medicine.

[61]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[62]  Sangram S. Sisodia,et al.  γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.

[63]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[64]  P. Greengard,et al.  Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.

[65]  W. Engel,et al.  Novel Immunolocalization of α‐Synuclein in Human Muscle of Inclusion‐Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions , 2000, Journal of neuropathology and experimental neurology.

[66]  C. Southan,et al.  ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. , 2000, Molecular and cellular neurosciences.

[67]  E. Holme,et al.  Mitochondrial DNA Deletions in Muscle Fibers in Inclusion Body Myositis , 1995, Journal of neuropathology and experimental neurology.

[68]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[69]  E. Masliah,et al.  Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases , 2007, NeuroMolecular Medicine.

[70]  W. Engel,et al.  Inclusion-body myositis , 2006, Neurology.

[71]  W. Engel,et al.  beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. , 1993, Neuroreport.

[72]  F. Mastaglia,et al.  Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects , 2003, Muscle & nerve.

[73]  W. Engel,et al.  Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  P. Crofton,et al.  Diagnostic Utility of a Low-Dose Gonadotropin-Releasing Hormone Test in the Context of Puberty Disorders , 2004, Hormone Research in Paediatrics.

[75]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  G. Vattemi,et al.  Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers , 2004, Neurology.

[77]  W. Engel,et al.  Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms , 2002, Current opinion in neurology.

[78]  H. Atkins,et al.  Suppressing immunity in advancing MS , 2004, Neurology.

[79]  W. Engel,et al.  Strong immunoreactivity of β-amyloid precursor protein, including the β-amyloid protein sequence, at human neuromuscular junctions , 1992, Neuroscience Letters.

[80]  D. Selkoe Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman , 2003, Neurochemical Research.

[81]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[82]  R. Ellis,et al.  Medicine: Danger — misfolding proteins , 2002, Nature.

[83]  M. Franceschi,et al.  Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms , 2002, Neurobiology of Aging.

[84]  S. Bhasin,et al.  Role of myostatin in metabolism , 2004, Current opinion in clinical nutrition and metabolic care.

[85]  P. Højrup,et al.  Proteasomal Inhibition by α-Synuclein Filaments and Oligomers* , 2004, Journal of Biological Chemistry.

[86]  W. W. Jong,et al.  The Molecular Chaperone aB-crystallin Enhances Amyloid Neurotoxicity , 1999 .

[87]  A. Cuello Intracellular and Extracellular Aβ, a Tale of Two Neuropathologies , 2005, Brain pathology.

[88]  Pietro Fratta,et al.  Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. , 2005, The American journal of pathology.

[89]  G. Martin,et al.  Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. , 1998, The American journal of pathology.

[90]  S. Dimauro,et al.  Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients , 1996, Annals of neurology.